Dermatology therapy developer Cutia Therapeutics (HKG: 2487) has announced that its CU-10201, a 4% minocycline foam agent for external use, has entered into priority review for the treatment of non-nodular moderate to severe acne vulgaris in individuals aged 9 and above in China.
CU-10201: A Novel Pediatric Dosage Form for Acne
CU-10201 is hailed as the world’s first and only external minocycline treatment for acne. Minocycline, a tetracycline antibiotic, is traditionally used to treat various bacterial infections and acne vulgaris, with current products primarily being oral medications. CU-10201 offers a new pediatric dosage form that could revolutionize acne treatment.
Advantages of Topical Minocycline Foam
Compared to other major anti-acne antibiotics and traditional oral drugs, topical minocycline foam like CU-10201 offers lower systemic drug exposure, fewer side effects, lower drug resistance, and potentially higher patient compliance. The phase III clinical trial data analysis in China demonstrates that CU-10201 has significant efficacy and good safety in treating acne, with the added benefit of reducing common side effects associated with oral minocycline.-Fineline Info & Tech
